A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of BCI 838 in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
At a glance
- Drugs BCI 838 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors BrainCells
- 05 Dec 2012 Results have been reported in a BrainCells media release.
- 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History